• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
CONCLUSION: These results suggest that activation of MEK is involved in both primary and acquired resistance to cetuximab and the inhibition of EGFR and MEK could be a strategy for overcoming anti-EGFR resistance in CRC patients. PMID: 24812410 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 8, 2014 Category: Cancer & Oncology Authors: Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E Tags: Clin Cancer Res Source Type: research

Increased TGFα as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
CONCLUSIONS: These results suggest that overexpression of TGFα through induction of EGFR-MET interaction contributes to cetuximab resistance in CRC cells. PMID: 24122793 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 11, 2013 Category: Cancer & Oncology Authors: Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'aiuto E, Berrino L, Bianco R, Ciardiello F Tags: Clin Cancer Res Source Type: research